Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2023

05.07.2023 | case report

Hepatosplenic T-cell lymphoma with hemophagocytic lymphohistiocytosis, revealed by fever of unknown origin

verfasst von: Kaoutar Meliani, Noufissa Alami Dribi, Widad Rhandour, Afaf Amarti Riffi, Zineb Khammar, Rhyzlane Berrady

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Summary

The unusual peripheral lymphoma known as hepatosplenic T‑cell lymphoma (HSTCL) is a rare hematologic cancer. In this report, we discuss a case of HSTCL with hemophagocytic lymphohistiocytosis that was discovered due to a prolonged fever in a 27-year-old woman with no prior medical history. Infectious and autoimmune diseases were ruled out during the etiological review. Histopathological analysis of the bone marrow revealed hemophagocytosis. A diagnostic splenectomy was performed after the patient’s clinical condition worsened, showing no response to corticosteroids, and notable splenomegaly and hepatomegaly were observed on the positron emission tomography (PET) scan. The diagnosis of HSTCL was confirmed through pathological examination of the surgical specimens. In addition, a complementary genetic analysis revealed a gamma-delta T‑cell lymphoma. Hemophagocytic lymphohistiocytosis remains a diagnostic and therapeutic challenge, and physicians should always consider the possibility of an underlying hematologic disorder. Our case highlights the difficulties in diagnosing HSTCL due to the various possible causes of prolonged fever of unknown origin, as well as the nonspecific clinical presentation and the absence of peripheral lymphadenopathy. Our report discusses a new case of HSTCL associated with hemophagocytic lymphohistiocytosis to raise awareness among physicians about this rare entity. This association can be confusing and may lead to delays in diagnosis and thus worsening prognosis.
Literatur
2.
Zurück zum Zitat Foss FM, Horwitz SM, Civallero M, et al. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol. 2020;95(2):151–5.CrossRefPubMed Foss FM, Horwitz SM, Civallero M, et al. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol. 2020;95(2):151–5.CrossRefPubMed
3.
Zurück zum Zitat Nosari A, Oreste PL, Biondi A, et al. Hepato-splenic gammadelta T‑cell lymphoma: a rare entity mimicking the hemophagocytic syndrome. Am J Hematol. 1999;60(1):61–5. https://doi.org/10.1002/(sici)1096-8652(199901)60:1〈61::aid-ajh10〉3.0.co;2‑l.CrossRefPubMed Nosari A, Oreste PL, Biondi A, et al. Hepato-splenic gammadelta T‑cell lymphoma: a rare entity mimicking the hemophagocytic syndrome. Am J Hematol. 1999;60(1):61–5. https://​doi.​org/​10.​1002/​(sici)1096-8652(199901)60:1〈61::aid-ajh10〉3.0.co;2‑l.CrossRefPubMed
4.
Zurück zum Zitat Thai A, Prindiville T. Hepatosplenic T‑cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4(5):511–22.CrossRefPubMed Thai A, Prindiville T. Hepatosplenic T‑cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4(5):511–22.CrossRefPubMed
5.
Zurück zum Zitat Yabe M, Medeiros LJ, Daneshbod Y, et al. Hepatosplenic T‑cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor‑α inhibitor therapy and literature review. Ann Diagn Pathol. 2017;26:16–22.CrossRefPubMed Yabe M, Medeiros LJ, Daneshbod Y, et al. Hepatosplenic T‑cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor‑α inhibitor therapy and literature review. Ann Diagn Pathol. 2017;26:16–22.CrossRefPubMed
6.
Zurück zum Zitat Cho MW, Chin BB. 18F-FDG PET/CT findings in hepatosplenic Gamma-Delta T‑cell lymphoma: case reports and review of the literature. Am J Nucl Med Mol Imaging. 2018;8(2):137–42.PubMedPubMedCentral Cho MW, Chin BB. 18F-FDG PET/CT findings in hepatosplenic Gamma-Delta T‑cell lymphoma: case reports and review of the literature. Am J Nucl Med Mol Imaging. 2018;8(2):137–42.PubMedPubMedCentral
7.
Zurück zum Zitat Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2017;23(11):1826–38.CrossRefPubMed Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2017;23(11):1826–38.CrossRefPubMed
8.
Zurück zum Zitat Parikh SA, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484–92.CrossRefPubMed Parikh SA, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484–92.CrossRefPubMed
14.
Zurück zum Zitat Chamseddin B, Des Marques E, Dominguez UN, et al. Refractory macrophage activation syndrome in the setting of adult-onset Still disease with hemophagocytic lymphohistiocytosis detected on skin biopsy treated with canakinumab and tacrolimus. J Cutan Pathol. 2019;46(7):528–31. https://doi.org/10.1111/cup.13466.CrossRefPubMed Chamseddin B, Des Marques E, Dominguez UN, et al. Refractory macrophage activation syndrome in the setting of adult-onset Still disease with hemophagocytic lymphohistiocytosis detected on skin biopsy treated with canakinumab and tacrolimus. J Cutan Pathol. 2019;46(7):528–31. https://​doi.​org/​10.​1111/​cup.​13466.CrossRefPubMed
15.
Zurück zum Zitat Yabe M, Medeiros LJ, Daneshbod Y, et al. Hepatosplenic T‑cell lymphoma arising in patients with immunodysregularity disorders: a study of 7 patients who did not receive tumor necrosis factor‑α inhibitor therapy and literature review. Ann Diagn Pathol. 2017;26:16–22.CrossRefPubMed Yabe M, Medeiros LJ, Daneshbod Y, et al. Hepatosplenic T‑cell lymphoma arising in patients with immunodysregularity disorders: a study of 7 patients who did not receive tumor necrosis factor‑α inhibitor therapy and literature review. Ann Diagn Pathol. 2017;26:16–22.CrossRefPubMed
16.
Zurück zum Zitat Paes VR, de Lima PP, Siqueira SAC. Hemophagocytic lymphohistiocytosis associated with hepatosplenic T‑cell lymphoma: case report. Autops Case Rep. 2014;4(4):19–24.CrossRefPubMedPubMedCentral Paes VR, de Lima PP, Siqueira SAC. Hemophagocytic lymphohistiocytosis associated with hepatosplenic T‑cell lymphoma: case report. Autops Case Rep. 2014;4(4):19–24.CrossRefPubMedPubMedCentral
17.
18.
Zurück zum Zitat Horwitz SM, Ansell S, Ai WZ, et al. T‑cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(3):285–308.CrossRefPubMed Horwitz SM, Ansell S, Ai WZ, et al. T‑cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(3):285–308.CrossRefPubMed
Metadaten
Titel
Hepatosplenic T-cell lymphoma with hemophagocytic lymphohistiocytosis, revealed by fever of unknown origin
verfasst von
Kaoutar Meliani
Noufissa Alami Dribi
Widad Rhandour
Afaf Amarti Riffi
Zineb Khammar
Rhyzlane Berrady
Publikationsdatum
05.07.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00897-y

Weitere Artikel der Ausgabe 3/2023

memo - Magazine of European Medical Oncology 3/2023 Zur Ausgabe